Previous issue | Volume 92 | ESPE2019 | Next issue

58th Annual ESPE

Vienna, Austria
19 Sep 2019 - 21 Sep 2019

Card image cap
The theme of this year’s meeting is Variety and Variation in Paediatric Endocrinology. Join us in Vienna to explore the diversity we encounter in our discipline and the care that we have to exercise when using the term “normality”. Whilst gaining an update on the latest treatments, clinical best practice and cutting edge research in the field of paediatric endocrinology.

Poster Category 1

Bone, Growth Plate and Mineral Metabolism

hrp0092p1-14 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Refractory Hypercalcemia After Denosumab Treatment in Pediatric Age: A Case Report

Deodati Annalisa , Ubertini Graziamaria , Grossi Armando , Inzaghi Elena , Paone Laura , Maria Milano Giuseppe , Cappa Marco , Fintini Danilo

Background: Denosumab is a new class of antiresorptive medication and a fully human monoclonal antibody of the IgG2 immunoglobulin isotype to RANKL. In fact, it binds with high affinity and specificity to RANKL, mimicking the inhibitory effects of Osteoprotegerin, resulting in rapid suppression of bone resorption. Denosumab is commonly used also in pediatric age for treatment of osteoporosis, malignancies, and other benign bone lesions, such as fibrous dysplas...

hrp0092p1-15 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

The Overweight and Obesity Decrease the Growth Potential in Mexican Children and Adolescents

Miranda-Lora América Liliana , Espinosa-Espíndola Montserrat , López-González Desireé , Loyo Mariana-Sánchez-Curiel , Dies Pilar , Klünder-Klünder Miguel

Background: The bone age (BA) assess the skeletal maturity and determine the children linear growth. Mexican children have a slightly delay in skeletal maturity before 10 years, but they reach in mean a BA 1 year in advance at the end of the puberty. On the other hand, Mexico has a high prevalence of childhood obesity and the adiposity has been associated with the BA advance in other populations. For the above, the overweight and obesity could be impact in the...

hrp0092p1-16 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Normocalcemic Hyperparathyroidism in Children

Papadimitriou Dimitrios T. , Dermitzaki Eleni , Kleanthous Kleanthis , Papadimitriou Anastasios , Mastorakos George

Normocalcemic primary hyperparathyroidism (NPHPT) has been recognized as a variant of primary hyperparathyroidism (PHPT) and it is characterized by elevated PTH with persistently normal concentrations of albumin-adjusted total and ionized calcium. It is related to increased risk in development of osteopenia/osteoporosis as well of parathyroid adenoma and hypercalcemia/hypercalciuria. In order to identify biochemical disorders of PTH in normocalcemic children we performed in al...

hrp0092p1-17 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Serum Testosterone Level at the Age of 12 is an Important Determinant of the Following Gain of Bone Mineral Apparant Density in 18-year Old Males: a Longitudinal Study From Puberty

Tamme Reeli , Jürimäe Jaak , Remmel Liina , Mäestu Evelin , Purge Priit , Mengel Eva , Tillmann Vallo

Background: Many cross-sectional studies have demonstrated that serum testosterone concentration is an important biochemical predictor of bone mineral density in young males, but to our knowledge, no longitudinal studies have been carried out to support these cross-sectional data.Aims: to examine the associations between serum testosterone concentration at the age of 12 and the following gain in bone mineral density unti...

hrp0092p1-18 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Nephrocalcinosis in Children with X-Linked Hypophosphatemia: Prevalence and Risks Factors

de Truchis Camille , Zhukouskaya Volha , Auger Martin , Rothenbuhler Anya , Linglart Agnès , Grapin Mathilde

X-linked hypophosphatemia (XLH) is diagnosed in children with clinical and or radiological signs of rickets, impaired growth velocity, low serum phosphate levels associated with renal phosphate wasting, in the absence of vitamin D or calcium deficiency. Conventional treatment is made of phosphate and active vitamin D. However, nephrocalcinosis has been identified as a complication of this therapy. Its prevalence is about 25-40% in adult XLH treated patients. It was never c...

hrp0092p1-20 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Long-term Teriparatide (rhPTH) Treatment in Children with Syndromic Hypoparathyroidism

Buganza Raffaele , Tuli Gerdi , Matarazzo Patrizia , Tessaris Daniele , De Sanctis Luisa

Background: Hypoparathyroidism is characterized by absence or inadequately low circulating concentrations of parathyroid hormone, resulting in hypocalcaemia, hyperphosphataemia and elevated fractional excretion of calcium in the urine. The use of activated vitamin D analogues and calcium supplements are recommended as the primary therapy. To avoid vitamin D and calcium side effects, subcutaneous recombinant human parathormone [rhPTH (1-34)] has been proposed f...

hrp0092p1-21 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Dual X-ray Absorptiometry in Children With Hypophosphatasia Treated with Asfotase Alfa: A Pooled Post Hoc Analysis

Simmons Jill H. , Rush Eric T. , Petryk Anna , Zhou Shanggen , Martos-Moreno Gabriel Á.

Hypophosphatasia (HPP) is a rare, inherited, systemic disease characterized by deficient tissue-nonspecific alkaline phosphatase activity. Common manifestations in children include impaired skeletal mineralization, short stature, and reduced physical function. Asfotase alfa is an enzyme replacement therapy approved for treatment of patients of any age with pediatric-onset HPP. The utility of dual X-ray absorptiometry (DXA) as a diagnostic tool or measure of treatment effective...

hrp0092p1-22 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Differences in Bone Strength and Cortical Bone Parameters in Young Swedish Women with Type 1 Diabetes

Kristiansen Eva , Novak Daniel , Forsander Gun , Svedlund Anna , Magnusson Per , Swolin-Eide Diana

Background: The incidence of Type 1 diabetes (T1D) is rising globally and fractures are common.Objective: To investigate bone health in young females with a T1D duration of at least 10 years in relation to healthy, matched controls.Subjects: Twenty-three Swedish females, aged 19.2– 27.9 years, with a T1D duration of ≥10 years, were recruited from the Swedish National Dia...

hrp0092p1-23 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Increased Prevalence of Overweight and Obesity and its Clinical Predictors in Children Affected by X-Linked Hypophosphatemia

Zhukouskaya Volha , Rothenbuhler Anya , Colao Annamaria , Di Somma Carolina , Kamenicky Peter , Trabado Séverine , Prié Dominique , Audrain Christelle , Barosi Anna , Kyheng Christèle , Lambert Anne-Sophie , Linglart Agnès

Background/Aim: X-linked hypophosphatemia (XLH) is a rare disease caused by inactivating mutations in the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene, characterized by chronic hypophosphatemia. XLH children present with progressive skeletal deformities (leg bowing, waddling gait, poor growth and disproportional short stature), dental abscesses, and craniosynostosis. Most affected children have been treated so far with multiple dail...

hrp0092p1-24 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Novel Homozygous LRP5 Mutations in Patients with Osteoporosis-Pseudoglioma Syndrome

Saffari Fatemeh , Heidari Abolfazl , Esmailzadehha Neda , Homaei Ali

Background: Osteoporosis pseudoglioma syndrome (OPPG) characterized by congenital or early onset blindness with severe juvenile onset osteoporosis. OPPG is a rare autosomal recessive disorder due to loss of function mutation in the low-density lipoprotein receptor like protein 5 (LRP5).Methods: Two patients (siblings) underwent clinical examination, including a complete ophthalmic evaluation. Diagnosis of OPPG was based ...